<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04109391</url>
  </required_header>
  <id_info>
    <org_study_id>TX05-03E</org_study_id>
    <nct_id>NCT04109391</nct_id>
  </id_info>
  <brief_title>Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03</brief_title>
  <official_title>A Double-blinded Extension Study to Provide Adjuvant Treatment With Single Agent Herceptin® or TX05 and Assess Continued Safety and Immunogenicity in Subjects With HER2-positive Early Breast Cancer Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanvex BioPharma USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanvex BioPharma USA, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an extension study to provide adjuvant treatment with single agent Herceptin or TX05
      and assess continued safety and immunogenicity in subjects with HER2-positive early breast
      cancer following neoadjuvant treatment and surgical resection in Protocol TX05-03.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 23, 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Adverse Events</measure>
    <time_frame>Assessed at all visits through end of treatment (Week 45) or Early Termination visit. Each cycle is 3 weeks.</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity Assessments</measure>
    <time_frame>Assessed from first infusion through end of treatment (Week 45) or Early Termination visit. Each cycle is 3 weeks.</time_frame>
    <description>Titer of anti-drug antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-Free Survival</measure>
    <time_frame>Through study completion/end of treatment (Week 45).</time_frame>
    <description>Randomization in neoadjuvant study to documentation of first failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Through study completion/end of treatment (Week 45).</time_frame>
    <description>Randomization in neoadjuvant study until death of any cause</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>HER2-positive Breast Cancer</condition>
  <condition>Early-stage Breast Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Breast Neoplasms</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Test Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV trastuzumab (TX05) 8 mg/kg loading dose and then 6 mg/kg every 3 weeks for up to 13 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV trastuzumab (Herceptin) TX05 8 mg/kg loading dose and then 6 mg/kg every 3 weeks for up to 13 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TX05 (trastuzumab)</intervention_name>
    <description>Subjects will receive up to 13 cycles of adjuvant treatment.</description>
    <arm_group_label>Test Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Herceptin (trastuzumab)</intervention_name>
    <description>Subjects will receive up to 13 cycles of adjuvant treatment.</description>
    <arm_group_label>Reference Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent.

          -  Females ≥ 18 years of age.

          -  Completed neoadjuvant treatment (regardless of treatment arm) in the TX05/ Herceptin
             neoadjuvant study and the investigator believes the subject requires continued access
             to single agent trastuzumab in order to continue deriving clinical benefit.

          -  Successfully undergone surgical resection of their primary tumor with no evidence of
             residual disease (as determined by local assessment) and no other adjuvant therapy,
             other than trastuzumab, is planned. However, subjects will be allowed to receive
             hormonal therapy if they have hormone receptor positive tumors. Subjects will also be
             allowed to receive adjuvant radiation therapy, if required by their treating
             physician.

          -  Able to comply with the study protocol.

          -  Female subjects of childbearing potential must have a negative serum pregnancy test
             within 14 days of first administration of study drug and agree to use effective
             contraception (hormonal contraceptive, intrauterine device, diaphragm with spermicide,
             or condom with spermicide) throughout the study period and for 7 months after last
             administration of study drug.

        Exclusion Criteria:

          -  Breast cancer metastases or residual disease post operatively (as determined by local
             assessment).

          -  History or presence of a medical condition or disease that in the investigator's
             opinion would place the subject at an unacceptable risk for study participation.

          -  Lactating or pregnant female.

          -  Women of childbearing potential who do not consent to use highly effective methods of
             birth control (e.g. true abstinence [periodic abstinence {e.g. calendar ovulation,
             symptothermal, post-ovulation methods} and withdrawal are not acceptable methods of
             contraception], sterilization, or other non-hormonal forms of contraception) during
             treatment and for at least 7 months after the last administration of study drug.
             Subjects must agree to not breast-feed while receiving study drug.

          -  Any condition that in the opinion of the Investigator represents an obstacle for study
             conduct and/or represents a potential unacceptable risk for subjects.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bonnie Mills, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Tanvex BioPharma USA, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1003E</name>
      <address>
        <city>Gomel</city>
        <zip>246012</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1006E</name>
      <address>
        <city>Grodno</city>
        <zip>230017</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1008E</name>
      <address>
        <city>Lesnoy</city>
        <zip>223040</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1002E</name>
      <address>
        <city>Minsk</city>
        <zip>220013</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1001E</name>
      <address>
        <city>Vitebsk</city>
        <zip>210603</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 4001E</name>
      <address>
        <city>Temuco</city>
        <zip>2520598</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 4002E</name>
      <address>
        <city>Vina del Mar</city>
        <zip>4810469</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 5006E</name>
      <address>
        <city>Batumi</city>
        <zip>6000</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 5002E</name>
      <address>
        <city>Batumi</city>
        <zip>6010</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 5001E</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 5005E</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 5010E</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 6003E</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 7031E</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 7019E</name>
      <address>
        <city>Bangalore</city>
        <zip>560027</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 7036E</name>
      <address>
        <city>Hyderabad</city>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 7001E</name>
      <address>
        <city>Nashik</city>
        <zip>422002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 7015E</name>
      <address>
        <city>Pune</city>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 7017E</name>
      <address>
        <city>Vijayawada</city>
        <zip>520002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 2109E</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20234</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 2103E</name>
      <address>
        <city>Monterrey</city>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 2106E</name>
      <address>
        <city>Oaxaca</city>
        <zip>68000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 2110E</name>
      <address>
        <city>Tequisquiapan</city>
        <zip>76750</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 2108E</name>
      <address>
        <city>Zapopan</city>
        <zip>45030</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1101E</name>
      <address>
        <city>Arequipa</city>
        <zip>04001</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1107E</name>
      <address>
        <city>Arequipa</city>
        <zip>04001</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1104E</name>
      <address>
        <city>Chiclayo</city>
        <zip>14001</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1112E</name>
      <address>
        <city>Lima Cercado</city>
        <zip>15082</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1108E</name>
      <address>
        <city>San Borja</city>
        <zip>41</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1102E</name>
      <address>
        <city>San Isidro</city>
        <zip>15073</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1109E</name>
      <address>
        <city>Surquillo</city>
        <zip>15038</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1103E</name>
      <address>
        <city>Trujillo</city>
        <zip>13001</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1211E</name>
      <address>
        <city>Cebu city</city>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1212E</name>
      <address>
        <city>Davao City</city>
        <zip>8000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1209E</name>
      <address>
        <city>Quezon City</city>
        <zip>1101</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1213E</name>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Invesitgational Site 1210E</name>
      <address>
        <city>Santo Tomas</city>
        <zip>4234</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1513E</name>
      <address>
        <city>Sochi</city>
        <state>Krasnodar Region</state>
        <zip>354057</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1535E</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1502E</name>
      <address>
        <city>Kaluga</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1505E</name>
      <address>
        <city>Kislino</city>
        <zip>305524</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1529E</name>
      <address>
        <city>Krasnodar</city>
        <zip>350040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1512E</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660133</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1507E</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1511E</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1503E</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1509E</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1537E</name>
      <address>
        <city>Orenburg</city>
        <zip>460021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1526E</name>
      <address>
        <city>Pesochnyy</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1510E</name>
      <address>
        <city>Pushkin</city>
        <zip>196603</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1521E</name>
      <address>
        <city>Rostov-Na-Donu</city>
        <zip>344037</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1516E</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1524E</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1525E</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1506E</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1501E</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1523E</name>
      <address>
        <city>Sankt-peterburg</city>
        <zip>191104</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1508E</name>
      <address>
        <city>Saransk</city>
        <zip>430032</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1534E</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1820E</name>
      <address>
        <city>Antonivka</city>
        <zip>73000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1803E</name>
      <address>
        <city>Chernihiv</city>
        <zip>14029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1808E</name>
      <address>
        <city>Chernihiv</city>
        <zip>14029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1821E</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1811E</name>
      <address>
        <city>Kiev</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1802E</name>
      <address>
        <city>Kiev</city>
        <zip>04107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1819E</name>
      <address>
        <city>Kropyvnytskyi</city>
        <zip>25006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1814E</name>
      <address>
        <city>Kropyvnytskyi</city>
        <zip>25011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1804E</name>
      <address>
        <city>Kryvyi Rih</city>
        <zip>50048</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1815E</name>
      <address>
        <city>Kyiv</city>
        <zip>03022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1809E</name>
      <address>
        <city>Kyiv</city>
        <zip>03126</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1810E</name>
      <address>
        <city>Odesa</city>
        <zip>65055</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1806E</name>
      <address>
        <city>Sumy</city>
        <zip>40022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1822E</name>
      <address>
        <city>Ternopil</city>
        <zip>46023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1818E</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanvex Investigational Site 1813E</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69059</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Chile</country>
    <country>Georgia</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

